pirfenidone has been researched along with Non-alcoholic Fatty Liver Disease in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, Z; Deng, L; Geng, X; Hu, L; Jiao, S; Li, Z; Ren, Q; Wang, B; Yang, Y; Zhang, L; Zhou, Z | 1 |
| Chen, S; Li, F; Xie, R; Yang, L; Yu, B | 1 |
| Armendáriz-Borunda, J; Gutiérrez-Cuevas, J; Monroy-Ramírez, HC; Sandoval-Rodríguez, A; Santos-García, A; Vazquez-Del Mercado, M | 1 |
| Armendáriz-Borunda, J; Escutia-Gutiérrez, R; García-Bañuelos, J; Monraz-Méndez, CA; Rodríguez-Sanabria, JS; Sandoval-Rodríguez, A; Santos-García, A | 1 |
| Chen, G; Kaneko, S; Nagashimada, M; Nagata, N; Ni, Y; Ota, T; Xu, L; Zhuge, F | 1 |
| Furuke, S; Hata, KI; Ikeda, K; Itoh, M; Komiya, C; Miyachi, Y; Mori, K; Nakabayashi, K; Ochi, K; Ogawa, Y; Shiba, K; Shimazu, N; Suganami, T; Tanaka, M; Tsuchiya, K; Yamaguchi, S | 1 |
6 other study(ies) available for pirfenidone and Non-alcoholic Fatty Liver Disease
| Article | Year |
|---|---|
Discovery of new and highly effective quadruple FFA1 and PPARα/γ/δ agonists as potential anti-fatty liver agents.
Topics: Animals; Chenodeoxycholic Acid; Drug Discovery; Gene Expression Regulation; Humans; Hypoglycemic Agents; Liver Cirrhosis; Male; Mice, Inbred C57BL; Mice, Inbred ICR; Models, Molecular; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Peroxisome Proliferator-Activated Receptors; Protein Binding; Receptors, G-Protein-Coupled; Structure-Activity Relationship | 2022 |
Pirfenidone attenuates nonalcoholic fatty liver disease through activation of the nuclear factor erythroid 2-related factor 2 (Nrf2) signaling pathway.
Topics: Animals; Antioxidants; Cholesterol; Diet, High-Fat; Liver; Mice; Mice, Inbred C57BL; NF-E2-Related Factor 2; Non-alcoholic Fatty Liver Disease; Signal Transduction | 2023 |
Prolonged-release pirfenidone prevents obesity-induced cardiac steatosis and fibrosis in a mouse NASH model.
Topics: Animals; Body Weight; Diet, High-Fat; Disease Models, Animal; Fibrosis; Heart Diseases; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; PPAR alpha; Pyridones; Random Allocation | 2021 |
Pirfenidone modifies hepatic miRNAs expression in a model of MAFLD/NASH.
Topics: Animals; Biomarkers; Collagen Type I; Cytokines; Disease Models, Animal; Disease Susceptibility; Fatty Liver; Gene Expression Regulation; Immunohistochemistry; Inflammation Mediators; Lipid Metabolism; Liver Function Tests; Male; Mice; MicroRNAs; Non-alcoholic Fatty Liver Disease; Pyridones | 2021 |
Pirfenidone prevents and reverses hepatic insulin resistance and steatohepatitis by polarizing M2 macrophages.
Topics: Animals; Diet, High-Fat; Disease Models, Animal; Insulin Resistance; Liver; Liver Cirrhosis; Macrophages; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Protective Agents; Pyridones; RAW 264.7 Cells | 2019 |
Antifibrotic effect of pirfenidone in a mouse model of human nonalcoholic steatohepatitis.
Topics: Animals; Apoptosis; Caspase 3; Caspase 8; Cells, Cultured; Diet, Western; Disease Models, Animal; Feeding Behavior; Hepatocytes; Humans; Inflammation; Liver; Liver Cirrhosis; Mice, Inbred C57BL; Mice, Knockout; Non-alcoholic Fatty Liver Disease; Pyridones; Receptor, Melanocortin, Type 4; Tumor Necrosis Factor-alpha; Up-Regulation | 2017 |